Icotyde (icotrokinra) / Protagonist Therap, J&J - LARVOL DELTA

Histologic and Endoscopic Efficacy of Icotrokinra, a First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Outcomes From the ANTHEM-UC Study (ACG 2026) - " Participants (pts) had a modified Mayo score of 5â9 inclusive, a Mayo endoscopy subscore (MES) â¥2, and prior inadequate response or intolerance (IR) to advanced therapies (ADT-IR) or IR to corticosteroids, azathioprine, or mercaptopurine. At Week 12, compared with PBO, greater proportions of pts in the icotrokinra 100, 200, and 400 mg groups achieved endoscopic remission, histologic remission, histologic improvement, and histologic remission & clinical remission ( Figure ). The 400 mg dose group demonstrated the greatest numerical differences versus PBO at Week 12. At Week 28, pts in all icotrokinra dose groups showed clinically meaningful (â¥10%) improvements compared with PBO across all endpoints (excepting the 200 mg group for endoscopic remission)."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Novel Coronavirus Disease • Ulcerative Colitis • IL23A

Long-Term Efficacy and Safety of Icotrokinra, A First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Results From the ANTHEM-UC Long-Term Extension (ACG 2026) - "Abstract text will be released on Sunday, October 11, 2026, at 12:00 pm CT (1:00 pm ET) when the ACG 2026 embargo lifts."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra. (PubMed, Expert Opin Emerg Drugs) - No abstract available

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Long-term Durability and Safety of the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 2-year Findings From the ICONIC-TOTAL Randomized Controlled Trial (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • Dermatology • Immunology • Psoriasis

Johnson & Johnson...announced that the European Commission (EC) has granted approval for the Marketing Authorisation of ICOTYDE (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of adults and adolescent patients (aged ≥12 years and weighing ≥40 kg) with moderate-to-severe plaque psoriasis (Pso) who are candidates for systemic therapy (GlobeNewswire) - "The EC decision is supported by an unprecedented breadth of evidence within the Phase 3 ICONIC clinical development programme, which simultaneously evaluated icotrokinra in adults and adolescents aged 12 and older and weighing at least 40 kg with moderate-to-severe plaque Pso."

EMA approval • Plaque Psoriasis

Comparative Durability Of Response After Biologic Withdrawal: A Systematic Review Of Icotrokinra, Nemolizumab, And Bimekizumab Rebound Data. Defining A New "Treatment-Free Remission Probability Score" (EADV 2026) - No abstract available

Clinical • Review

Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis (EADV 2026) - No abstract available

P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of Four Phase 3 Placebo-Controlled Trials (EADV 2026) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

The Rebound Paradox Across Novel Oral Peptides: A Systematic Review of Treatment Withdrawal Effects from Icotrokinra and JAK Inhibitor Trials to Define a New Framework for "Disease Sovereignty" (EADV 2026) - No abstract available

Review

Durability of Systemic and Skin Pharmacodynamic Responses With Icotrokinra in Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Week 52 Results (EADV 2026) - No abstract available

P3 data • PK/PD data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Reduction of Skin CD8 TRMs in Icotrokinra-Treated Participants With Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Results Through Week 52 (EADV 2026) - No abstract available

P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients With Moderate-to-Severe Plaque Psoriasis (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis (EADV 2026) - No abstract available

Retrospective data • Review • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Durability of Icotrokinra Effect in Participants With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Pooled Analysis of One-Year Outcomes From the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials (EADV 2026) - No abstract available

P3 data • Retrospective data • Dermatology • Immunology • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative Efficacy of Oral Icotrokinra versus Injectable IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis (EADV 2026) - No abstract available

Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IL23A

Protagonist Therapeutics Announces $300 Million Share Repurchase Program (ACCESS Newswire) - "The Company intends to fund the share repurchases from its cash, cash equivalents, and marketable securities, and from royalties and other payments received under the Company's collaboration arrangements with Takeda related to MIMRYLO (rusfertide) and with Johnson & Johnson related to ICOTYDE (icotrokinra)....The Company expects to receive the payments from Takeda in the fourth quarter of 2026."

Commercial • Plaque Psoriasis • Polycythemia Vera

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials. (PubMed, Dermatol Ther (Heidelb)) - P3 | "In this analysis of 2400 icotrokinra-treated participants with psoriasis followed through 1 year, icotrokinra demonstrated favorable safety; event rates through week 16 were similar to placebo and remained consistent through week 52."

Journal • P3 data • Dermatology • Immunology • Infectious Disease • Psoriasis • IL23A

SINGLE-CELL AND SPATIAL PROFILING OF CELLULAR COMPOSITION AND SIGNALING CHANGES FOLLOWING ICOTROKINRA TREATMENT IN ULCERATIVE COLITIS: RESULTS FROM ANTHEM-UC (UEGW 2026) - No abstract available

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

HISTOLOGIC AND ENDOSCOPIC EFFICACY OF ICOTROKINRA, A FIRST-IN-CLASS TARGETED ORAL PEPTIDE THAT PRECISELY BLOCKS THE IL-23 RECEPTOR, IN ULCERATIVE COLITIS: OUTCOMES FROM THE ANTHEM-UC STUDY (UEGW 2026) - No abstract available

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

PLASMA, COLON TISSUE AND FECAL PHARMACOKINETICS OF ICOTROKINRA IN ANTHEM-UC: RESULTS THROUGH WEEK 28 FROM A PHASE 2B DOSE‑RANGING STUDY IN ULCERATIVE COLITIS PATIENTS (UEGW 2026) - No abstract available

Clinical • P2b data • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

China approves J&J psoriasis pill Icotyde, says drugmaker (Reuters)

China approval • Immunology • Plaque Psoriasis

PN235. History Panel Part 2: From Ether to Engagement- Inspiring Innovations in Anesthesia Education (1 CME) (ASA 2026) - "The session will trace the growth of anesthesiology residencies in the United States and abroad and highlight creative ways to weave history into modern curricula. SessionLearningObjective1: Explain how the history of anesthesia informs and enriches contemporary medical and residency education.SessionLearningObjective2: Examine the evolution of medical education and anesthesiology residency training in the United States and internationally.SessionLearningObjective3: Evaluate the contributions of Ralph M. Waters, MD, to resident education and the development of anesthesia leadership globally."

CME • Anesthesia

The Efficacy of Oral Icotrokinra versus Injectable IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Comparative Meta-Analysis. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL23A

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety. (PubMed, J Dermatol) - "Older conventional systemic agents, such as cyclosporin, acitretin, or methotrexate, remain useful in selected settings, especially when treatment options are limited by cost or availability, when short-term disease control is needed, or when the patient prefers these treatments...Biologics targeting TNF-α or anti-IL-12/23p40 ustekinumab have established the biologic treatment era, and remain clinically relevant, especially for patients having psoriatic arthritis or prioritizing long-term safety...Targeted oral therapies increase options for patients who prefer non-injectable treatment; established or emerging agents include apremilast, deucravacitinib, icotrokinra, zasocitinib, envudeucitinib, and orismilast. Emerging IL-17-directed agents, including sonelokimab and izokibep, may further refine pathway targeting. Selection of treatment should be decided dependently on the completeness of skin clearance achieved, speed and duration of responses, effectiveness on..."

Journal • Review • Candidiasis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • TNFA

ICOTYDE (Icotrokinra): Oral IL-23 Receptor Antagonist (Yahoo Finance) - "...Protagonist remains eligible to receive up to $580 million in potential additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales with an approximate 7.25% weighted-average royalty rate at $4 billion in annual net sales and a 10% tier applying to the incremental annual sales above $4 billion. ICOTYDE is the first and only FDA-approved targeted oral peptide for moderate-to-severe plaque psoriasis."

Sales projection • Immunology • Plaque Psoriasis